Clinical trials: Geriatric Assessment
Hypercholesterolemia
A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)
Multiple-dose study to measure pharmacokinetics, pharmacodynamics and safety of bempedoic acid in pediatric participants 6 to 17 years of age with HeFH.
- Trial name
- CLEAR Path 1 (NCT05694260)
- Testing
- Bempedoic acid
- Where
- 24 sites in United States, Canada and 4 more
- Volunteers
- 31 people
- Sponsor
- Esperion Therapeutics, Inc.
Cystic Fibrosis, Pancreatic Exocrine Insufficiency
Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF)
This study will assess the effect of pancrelipase delayed release 12,000 unit capsules on fat and nitrogen absorption in subjects 7 - 11 with pancreatic exocrine insufficiency due to Cystic Fibrosis.
- Trial name
- NCT00690820
- Testing
- Pancrelipase Delayed Release
- Where
- 10 sites in United States
- Volunteers
- 17 people
- Sponsor
- Solvay Pharmaceuticals
Endometriosis
A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain
The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe…
- Trial name
- ELENA (NCT05560646)
- Testing
- OG-6219
- Where
- 86 sites in United States, Belgium and 9 more
- Volunteers
- 354 people
- Sponsor
- Organon and Co
Influenza
Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults
The present study is designed to evaluate the reactogenicity and immunogenicity of one or two booster administrations of an influenza pandemic candidate vaccine (GSK1562902A) in adults aged between 19 and 61 years, previously…
- Trial name
- NCT00506350
- Testing
- Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose, Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses
- Where
- Belgium
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Arterial Hypertension
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
To assess the efficacy and safety of sildenafil when added to patients with PAH who are taking bosentan as all or part of their background therapy.
- Trial name
- NCT00323297
- Testing
- Bosentan, Sildenafil Citrate
- Where
- 30 sites in United States, Australia and 8 more
- Volunteers
- 105 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Meningococcal Vaccine, rLP2086
A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.
This study is to look at a new vaccine that might prevent meningococcal disease, and to look at the safety of the new vaccine as well as how it is tolerated when given together with Repevax.
- Conditions
- Meningococcal Vaccine, rLP2086, Repevax, N Meningitidis Serogroup B
- Trial name
- NCT01323270
- Testing
- rLP2086, Repevax, Saline
- Where
- 36 sites in Finland, Germany and 1 more
- Volunteers
- 753 people, healthy volunteers welcome
- Sponsor
- Pfizer
Herpes Zoster, Herpes Zoster Vaccine
Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
The purpose of this study is to assess the immunogenicity, reactogenicity and safety of the GSK Biologicals HZ/su candidate vaccine when its first dose is co-administered with Pneumovax 23™ vaccine in adults aged 50 years or…
- Trial name
- NCT02045836
- Testing
- Herpes Zoster vaccine GSK 1437173A, Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 865 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Age-Related Macular Degeneration
First-in-Human Study of LHA510 in Elderly Subjects and Patients With Age-Related Macular Degeneration
The purpose of this first-in-human study is to assess the local ocular and systemic safety and tolerability of LHA510 eye drops when administered at various concentrations and dosing frequencies.
- Trial name
- NCT02076919
- Testing
- LHA510 Ophthalmic Suspension, LHA510 Vehicle
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Influenza
Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different Suppliers
The purpose of this study is to assess the humoral immune response and safety of the parenteral formulation of the 2010/2011-season virosomal subunit influenza vaccine Inflexal V using two different HA antigen suppliers (AdImmune…
- Trial name
- NCT01412281
- Testing
- Virosomal influenza vaccine (AdImmune HA Antigen), Virosomal influenza vaccine (CSL HA Antigen)
- Where
- Switzerland
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Infertility
Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1)
This trial investigates the effects of FE 999049 compared to placebo.
- Trial name
- RITA-1 (NCT03740737)
- Testing
- Follitropin delta
- Where
- 23 sites in United States
- Volunteers
- 579 people
- Sponsor
- Ferring Pharmaceuticals
Influenza Caused by the Novel Influenza A (H1N1) Virus
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults
The purpose of the study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy adults.
- Trial name
- NCT00938639
- Testing
- CSL425
- Where
- Australia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Seqirus
Diabetes Mellitus, Type 2
Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old
The primary objective of this study is to determine if there will be a greater mean reduction from baseline in glycated hemoglobin (HbA1c) achieved after 26 weeks of oral double-blind add-on therapy of dapagliflozin or…
- Trial name
- NCT03199053
- Testing
- Dapagliflozin, Saxagliptin
- Where
- 122 sites in United States, Argentina and 21 more
- Volunteers
- 256 people
- Sponsor
- AstraZeneca
Respiratory Syncytial Virus Infections
A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above
The purpose of this study is to assess the lot-to-lot consistency in terms of immunogenicity and evaluate the safety and reactogenicity of 3 lots of the RSVPreF3 OA investigational vaccine administered as a single dose in adults…
- Trial name
- NCT05059301
- Testing
- RSVPreF3 OA investigational vaccine
- Where
- 19 sites in United States, Canada and 1 more
- Volunteers
- 770 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Migraine Disorders
Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1)
A study to assess the safety, tolerability, and single dose pharmacokinetics of a marketed drug in pediatric subjects with migraines.
- Trial name
- NCT00604812
- Testing
- rizatriptan benzoate (5 mg), rizatriptan benzoate (10 mg)
- Volunteers
- 31 people
- Sponsor
- Organon and Co
Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation
The primary objective of the study was to evaluate the efficacy of lumacaftor in combination with ivacaftor at Week 24 in participants aged 12 years and older with cystic fibrosis (CF) who are homozygous for the F508del mutation…
- Trial name
- TRAFFIC (NCT01807923)
- Testing
- Lumacaftor Plus Ivacaftor Combination, Ivacaftor
- Where
- 89 sites in United States, Australia and 9 more
- Volunteers
- 559 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation
The purpose of this study was to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis aged 6 to 11 years who have the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR)…
- Trial name
- ENVISION (NCT00909727)
- Testing
- Ivacaftor
- Where
- 29 sites in United States, Australia and 5 more
- Volunteers
- 52 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Schizophrenia
Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011)
This is a randomized, double-blind, 2-part clinical study of the safety, tolerability and pharmacokinetics of alternate elpipodect titration regimens.
- Trial name
- NCT04506905
- Testing
- Elpipodect
- Where
- 6 sites in United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Respiratory Syncytial Virus Infections
A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older
The purpose of the current study is to evaluate the immune response of the RSVPreF3 OA investigational vaccine in older adults (OA) at least (>=) 60 years of age (YOA) in China compared to OA in the same age range to be enrolled…
- Trial name
- NCT06551181
- Testing
- RSVPreF3 OA investigational vaccine
- Where
- 40 sites in China, Finland and 5 more
- Volunteers
- 2,620 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With Asthma
The purpose of this study was to assess the pharmacokinetics (PK) of fevipiprant (QAW039) delivered as a chewable tablet (CT) in pediatric asthma subjects aged 6 to < 12 years with asthma.
- Trial name
- NCT03650400
- Testing
- Fevipiprant
- Where
- 6 sites in United States
- Volunteers
- 11 people
- Sponsor
- Novartis Pharmaceuticals
Human Influenza
Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects
To evaluate the safety of a single intramuscular (IM) injection of trivalent adjuvanted influenza study vaccine, formulation 2012/2013, in elderly subjects and the antibody response to each influenza vaccine antigen, as measured…
- Trial name
- NCT01651104
- Testing
- Adjuvanted Trivalent Influenza Virus Vaccine (aTIV)
- Where
- Belgium
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines